Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial

What Was Tested

The paper reports a study of Retatrutide, published as a randomized controlled trial.

Retatrutide is a GIP, GLP-1, and glucagon triple hormone receptor agonist, under clinical development for type 2 diabetes, obesity, and related complications.

Who Took Part

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Because people in this Retatrutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Retatrutide study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Retatrutide could be set against what happens without it.

The primary endpoint was the change in HbA1c concentration from baseline to week 40.

A key secondary endpoint was the percentage change in bodyweight from baseline to week 40.

This trial is registered with ClinicalTrials.gov, NCT06354660, and is completed.

What Was Measured

The subject headings attached to it are Blood Glucose, Diabetes Mellitus, Type 2, Exercise, Glucagon-Like Peptide-1 Receptor Agonists, Glycated Hemoglobin, Glycemic Control and Hypoglycemic Agents.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Retatrutide.

The abstract goes on to report its results in about 9 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2026 (Lancet (London, England)), a journal based in England.

More context: the Retatrutide compound page, all human trials.